Presepsin诊断新生儿早发型败血症的系统综述与Meta分析
该系统综述与Meta分析评估了Presepsin诊断新生儿早发型败血症(EOS)的准确性。主要分析纳入12项研究、828名新生儿,合并敏感度0.93(95%CI 0.86-0.95)、特异度0.91(95%CI 0.85-0.95)。结论认为Presepsin是诊断EOS的准确生物标志物,但需临床试验评估其减少早期抗生素暴露的效用与安全性。
要点
- Presepsin诊断EOS合并敏感度0.93、特异度0.91,诊断比值比131.69。
- 特异度与纳入仅EOS或所有新生儿败血症的研究相关。
- 准确性不受胎龄、检测方法、国家或偏倚风险影响。
核心结论
- Presepsin是诊断新生儿早发型败血症的准确生物标志物。
- 需临床试验评估其减少早期抗生素暴露的效用与安全性,尤其早产儿。
研究设计与样本
- 系统综述与Meta分析,检索PubMed Medline、EMBASE、Web of Science和Google Scholar,无发表时间限制,限英文。
- 主要分析纳入12项研究、828名新生儿;次要分析纳入23项研究、1866名新生儿。
- 纳入标准为足月或早产新生儿、EOS诊断(主要分析为培养确诊,次要分析为临床或培养确诊)、初始评估时检测Presepsin。
- 采用QUADAS-2工具进行质量评估,随机效应模型合并数据。
主要发现
- 主要分析中,合并敏感度0.93(95%CI 0.86-0.95),合并特异度0.91(95%CI 0.85-0.95),诊断比值比131.69(95%CI 54.93-310.94)。
- 亚组分析显示Presepsin特异度与纳入仅EOS或所有新生儿败血症的研究相关。
- Presepsin准确性不受胎龄、化学发光酶免疫分析或酶联免疫吸附试验检测、研究国家或偏倚风险判断的影响。
- 次要分析中,准确性仅与检测类型显著相关。
关键数值与推荐
- 主要分析:12项研究、828名新生儿,合并敏感度0.93(95%CI 0.86-0.95),特异度0.91(95%CI 0.85-0.95),诊断比值比131.69(95%CI 54.93-310.94)。
- 次要分析:23项研究、1866名新生儿,准确性仅与检测类型显著相关。
临床怎么用
- Presepsin可作为新生儿EOS诊断的辅助生物标志物,具有较高敏感度和特异度。
- 其减少早期抗生素暴露的效用与安全性尚需临床试验验证,尤其早产儿。
局限性
- 主要分析仅纳入12项研究,样本量有限。
- 次要分析中EOS定义包含临床诊断,可能引入异质性。
- 检索限英文文献,可能存在语言偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neonatal early-onset sepsis (EOS) is a severe disease, particularly in preterm infants. Timely diagnosis can be challenging owing to unspecific presentation and questionable performance of the common markers of infection. Presepsin was recently proven to be a promising biomarker for the diagnosis of EOS. OBJECTIVE: To assess presepsin accuracy for the diagnosis of EOS. DATA SOURCES: PubMed Medline, EMBASE, Web of Science, and Google Scholar. No publication date restrictions were applied. The literature search was limited to the English language. Articles were checked for duplication. STUDY SELECTION: Inclusion criteria were studies that (1) included term or preterm newborns (defined as newborns with gestational age ≥37 weeks or <37 weeks, respectively); (2) included a diagnosis of EOS, defined as culture-proven sepsis for primary analysis and as either clinical or culture-proven sepsis for secondary analysis; and (3) assessed presepsin values during the initial workup for suspected EOS. Exclusion criteria were studies that (1) did not include EOS cases; (2) lacked data on presepsin sensitivity and/or specificity; and (3) were case reports, commentaries, or reviews. Two independent reviewers performed the study selection. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers performed data extraction and quality assessment. Quality assessment was performed using the Quality Assessment for Studies of Diagnostic Accuracy 2 tool, and data were reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data were pooled using a random-effects model. MAIN OUTCOMES AND MEASURES: The outcomes of interest for both the primary and secondary analyses were presepsin sensitivity, specificity, and diagnostic odds ratio for the diagnosis of EOS. RESULTS: A total of 12 studies of 245 (4.9%) met inclusion criteria for the primary analysis. Twenty-three studies of 245 (9.4%) met the inclusion criteria for the secondary analysis. In the primary analysis, among 12 studies and 828 newborns of any gestational age, pooled sensitivity and specificity were 0.93 (95% CI, 0.86-0.95) and 0.91 (95% CI, 0.85-0.95), respectively; pooled diagnostic odds ratio was 131.69 (95% CI, 54.93-310.94). Subgroup analysis showed that presepsin specificity was associated with the inclusion of only EOS or all neonatal sepsis. Presepsin accuracy was not associated with gestational age, measurement with chemiluminescence enzyme immunoassay or enzyme-linked immunosorbent assay testing, country where the study was performed, or risk of bias judgment. In the secondary analysis, among 23 studies and 1866 newborns, accuracy was significantly associated with only test type. CONCLUSIONS AND RELEVANCE: Results of this systematic review and meta-analysis suggest that presepsin was an accurate biomarker of EOS. Clinical trials are warranted to assess its usefulness and safety to reduce early antibiotic exposure, particularly in preterm newborns.
引用
- Poggi C, Lucenteforte E, Petri D, et al. Presepsin for the Diagnosis of Neonatal Early-Onset Sepsis: A Systematic Review and Meta-analysis. JAMA Pediatr. 2022. PMID: 35639395. doi:10.1001/jamapediatrics.2022.1647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。